| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:JC124
CAS:1638611-48-9
Purity:95% Package:5mg Remarks:S89890
|
Benzamide, 5-chloro-2-methoxy-N-[2-[4-[(methylamino)sulfonyl]phenyl]ethyl]- manufacturers
- JC124
-
- $58.00 / 1mg
-
2025-11-09
- CAS:1638611-48-9
- Min. Order:
- Purity: 99.64%
- Supply Ability: 10g
|
| | Benzamide, 5-chloro-2-methoxy-N-[2-[4-[(methylamino)sulfonyl]phenyl]ethyl]- Basic information |
| | Benzamide, 5-chloro-2-methoxy-N-[2-[4-[(methylamino)sulfonyl]phenyl]ethyl]- Chemical Properties |
| density | 1.304±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 11.54±0.30(Predicted) | | color | Light yellow to yellow |
| | Benzamide, 5-chloro-2-methoxy-N-[2-[4-[(methylamino)sulfonyl]phenyl]ethyl]- Usage And Synthesis |
| Uses | JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects[1]. | | Biological Activity | JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects[1].
JC124 shows selective inhibition of NLRP3 inflammasome formation and activation of caspase-1, and reduction of IL-1β both in vitro[1].
JC124 (100 mg/kg; i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI) treatment significantly decreases the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. JC124 also significantly reduces protein expression levels of NLRP3, ASC, IL-1 beta, TNFα, iNOS, and caspase-1[1]. | | in vivo | JC124 (100 mg/kg; i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI) treatment significantly decreases the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. JC124 also significantly reduces protein expression levels of NLRP3, ASC, IL-1 beta, TNFα, iNOS, and caspase-1[1]. | Animal Model: | Adult male Sprague-Dawley rats (3-4-months-old) bearing traumatic brain injury (TBI)[1] | | Dosage: | 100?mg/kg | | Administration: | i.p.; 4 doses; 30?min post-injury, 6, 24, and 30?h after TBI | | Result: | Significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. |
| | IC 50 | NLRP3 | | References | [1]. Ram Kuwar, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation. 2019 Apr 11;16(1):81. |
| | Benzamide, 5-chloro-2-methoxy-N-[2-[4-[(methylamino)sulfonyl]phenyl]ethyl]- Preparation Products And Raw materials |
|